Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18802279 | 0.87 | PTGS2 (0.35) | PTGS2PTGS1CA1CA2L3MBTL1 | |
| SCHEMBL18802300 | 0.78 | CA1 (0.37) | PTGS2PTGS1CA1CA2HTR2A | |
| SCHEMBL26684224 | 0.76 | PTGS2 (0.38) | PTGS2PTGS1CA1CA2L3MBTL1 | |
| SCHEMBL23299512 | 0.75 | CNR1 (0.36) | PTGS2PTGS1CA1CA2CNR1 | |
| SCHEMBL12930022 | 0.74 | CYP2C9 (0.43) | PTGS2PTGS1CA1CA2HTR2A | |
| SCHEMBL18809800 | 0.74 | CA1 (0.33) | PTGS2PTGS1CA1CA2HTR2A | |
| SCHEMBL409808 | 0.71 | CA1 (0.41) | PTGS2PTGS1CA1CA2HTR2A | |
| SCHEMBL18806835 | 0.71 | CA1 (0.37) | PTGS2PTGS1CA1CA2HTR2A | |
| SCHEMBL29323964 | 0.70 | PTGS2 (0.33) | PTGS2PTGS1CA1CA2L3MBTL1 | |
| SCHEMBL412435 | 0.69 | PTGS2 (0.36) | PTGS2PTGS1CA1CA2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022263801-A1 | PROCESS FOR PREPARING PEXIDARTINIB | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2022-12-22 | — | — | WO | disclosed |
| EP-3812040-A1 | COMPLEXES | Johnson Matthey Public Limited Company (GB) | 2021-04-28 | — | — | EP | disclosed |
| US-9777030-B2 | Complexes | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-10-03 | — | — | US | disclosed |
| US-20170120231-A1 | COMPLEXES | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-05-04 | — | — | US | disclosed |
| US-20170121357-A1 | COMPLEXES | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121357-A1 | COMPLEXES | CYCS, AP1M1, SOD1 | PTGS2 2067/4885PTGS1 2923/4885CA1 1111/4885 |
| US-20170120231-A1 | COMPLEXES | AP3M1, CYCS, AP1M1 | PTGS2 2845/4885PTGS1 3141/4885CA1 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.